SUNSHINE PHARMA (06887) announces a profitable result, with an expected net profit attributable to shareholders of approximately 270 million yuan for the year 2025, turning from a loss to a profit year-on-year.

SUNSHINE PHARMA (06887) announced that as of the end of the year 2025 on December 31, the Group expects to achieve a net profit attributable to shareholders of approximately RMB 270 million, representing an increase of about 228.57% compared to the net loss attributable to shareholders of approximately RMB 210 million in the same period last year. The expected increase is mainly due to a significant increase in the prevalence of influenza in the second half of 2025 compared to the same period last year. The Group's core product, Oseltamivir Phosphate, as the first choice for influenza prevention and treatment, has seen a significant increase in market demand year-on-year due to its precise efficacy and good brand reputation. At the same time, the Group adheres to a diversified market development strategy, continuously strengthens the construction of academic promotion system, optimizes channel layout and terminal coverage, enhances market penetration, brand influence, and commercial value of core products, and other business pipelines also show good performance. In the future, the Group will focus on innovation and international development strategies while continuing to consolidate the commercial layout of existing product business pipelines and solidifying market advantages. On one hand, the Group will further accelerate the research and commercialization process of key products such as innovative drugs and biologics, continuously enrich the product pipeline, and inject strong momentum into the long-term growth of the company's performance. On the other hand, the Group will continue to deepen technical exchanges and strategic cooperation with leading multinational pharmaceutical companies, steadily promote the international layout of products and markets, and continuously enhance the company's long-term sustainable development capabilities and comprehensive competitive strength.